TY - JOUR
T1 - Differential role of afferent and efferent renal nerves in the maintenance of early- and late-phase dahl S hypertension
AU - Foss, Jason D.
AU - Fink, Gregory D.
AU - Osborn, John W.
N1 - Publisher Copyright:
© 2016 the American Physiological Society.
PY - 2016/2
Y1 - 2016/2
N2 - Clinical data suggest that renal denervation (RDNX) may be an effective treatment for human hypertension; however, it is unclear whether this therapeutic effect is due to ablation of afferent or efferent renal nerves. We have previously shown that RDNX lowers arterial pressure in hypertensive Dahl salt-sensitive (S) rats to a similar degree observed in clinical trials. In addition, we have recently developed a method for selective ablation of afferent renal nerves (renal-CAP). In the present study, we tested the hypothesis that the antihypertensive effect of RDNX in the Dahl S rat is due to ablation of afferent renal nerves by comparing the effect of complete RDNX to renal-CAP during two phases of hypertension in the Dahl S rat. In the early phase, rats underwent treatment after 3 wk of high-NaCl feeding when mean arterial pressure (MAP) was ~140 mmHg. In the late phase, rats underwent treatment after 9 wk of high NaCl feeding, when MAP was ~170 mmHg. RDNX reduced MAP ~10 mmHg compared with sham surgery in both the early and late phase, whereas renal-CAP had no antihypertensive effect. These results suggest that, in the Dahl S rat, the antihypertensive effect of RDNX is not dependent on pretreatment arterial pressure, nor is it due to ablation of afferent renal nerves.
AB - Clinical data suggest that renal denervation (RDNX) may be an effective treatment for human hypertension; however, it is unclear whether this therapeutic effect is due to ablation of afferent or efferent renal nerves. We have previously shown that RDNX lowers arterial pressure in hypertensive Dahl salt-sensitive (S) rats to a similar degree observed in clinical trials. In addition, we have recently developed a method for selective ablation of afferent renal nerves (renal-CAP). In the present study, we tested the hypothesis that the antihypertensive effect of RDNX in the Dahl S rat is due to ablation of afferent renal nerves by comparing the effect of complete RDNX to renal-CAP during two phases of hypertension in the Dahl S rat. In the early phase, rats underwent treatment after 3 wk of high-NaCl feeding when mean arterial pressure (MAP) was ~140 mmHg. In the late phase, rats underwent treatment after 9 wk of high NaCl feeding, when MAP was ~170 mmHg. RDNX reduced MAP ~10 mmHg compared with sham surgery in both the early and late phase, whereas renal-CAP had no antihypertensive effect. These results suggest that, in the Dahl S rat, the antihypertensive effect of RDNX is not dependent on pretreatment arterial pressure, nor is it due to ablation of afferent renal nerves.
KW - Afferent renal nerves
KW - Dahl salt-sensitive rat
KW - Efferent renal nerves
KW - Renal denervation
UR - http://www.scopus.com/inward/record.url?scp=84956876181&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84956876181&partnerID=8YFLogxK
U2 - 10.1152/ajpregu.00408.2015
DO - 10.1152/ajpregu.00408.2015
M3 - Article
C2 - 26661098
AN - SCOPUS:84956876181
SN - 0363-6119
VL - 310
SP - R262-R267
JO - American Journal of Physiology - Regulatory Integrative and Comparative Physiology
JF - American Journal of Physiology - Regulatory Integrative and Comparative Physiology
IS - 3
ER -